Objective: There is a need for reliable serological assays to determine accurate estimates of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) seroprevalence. Most single target antigen assays have shown some limitations in Africa. To assess the performance of a multi-antigen assay, we evaluated a commercially available SARS-CoV-2 Multi-Antigen IgG assay for human coronavirus disease 2019 (COVID-19) in Nigeria.
Methods: Validation of the xMAP SARS-CoV-2 Multi-Antigen IgG assay was carried out using well-characterized SARS-CoV-2 reverse transcription polymerase chain reactive positive (97) and pre-COVID-19 pandemic (86) plasma panels. Cross-reactivity was assessed using pre-COVID-19 pandemic plasma specimens (213) from the 2018 Nigeria HIV/AIDS Indicator and Impact Survey (NAIIS).
Results: The overall sensitivity of the xMAP SARS-CoV-2 Multi-Antigen IgG assay was 75.3% [95% CI: 65.8%- 82.8%] and specificity was 99.0% [95% CI: 96.8%- 99.7%]. The sensitivity estimate increased to 83.3% [95% CI: 70.4%- 91.3%] for specimens >14 days post-confirmation of diagnosis. However, using the NAIIS pre-pandemic specimens, the false positivity rate was 1.4% (3/213).
Conclusions: Our results showed overall lower sensitivity and a comparable specificity with the manufacturer's validation. There appears to be less cross-reactivity with NAIIS pre-pandemic COVID-19 specimens using the xMAP SARS-CoV-2 Multi-Antigen IgG assay. In-country SARS-CoV-2 serology assay validation can help guide the best choice of assays in Africa.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC8974966 | PMC |
| http://journals.plos.org/plosone/article?id=10.1371/journal.pone.0266184 | PLOS |
Publication Analysis
Top Keywords
Similar Publications
Longitudinal analysis of SARS-CoV-2 IgG antibody durability in Puerto Rico.
Sci Rep
December 2024
Division of Vector-Borne Diseases, Centers for Disease Control and Prevention, San Juan, Puerto Rico.
Article Synopsis
- The study focuses on understanding how IgG antibody levels against SARS-CoV-2 behave over time in a group of people from Puerto Rico, especially in relation to vaccination and prior infections.
- Researchers conducted a longitudinal analysis with participants providing regular samples for testing from June 2020 to August 2022, allowing them to assess how antibody levels changed based on factors like vaccination status and the timing of infections.
- Findings revealed that a significant majority of participants showed increased antibody prevalence by the end of the study, with vaccinations contributing substantially to IgG levels, while a third booster dose was effective in enhancing and prolonging antibody response.
A multi-antigen vaccinia vaccine broadly protected mice against SARS-CoV-2 and influenza A virus while also targeting SARS-CoV-1 and MERS-CoV.
Front Immunol
December 2024
Shanghai Public Health Clinical Center and Institutes of Biomedical Sciences, Fudan University, Shanghai, China.
Introduction: Coronaviruses and influenza viruses are significant respiratory pathogens that cause severe disease burdens and economic losses for society. Due to their diversity and evolution, vaccines typically require periodic updating to remain effective. An additional challenge is imposed by the possible coinfection of SARS-CoV-2 and influenza, which could increase disease severity.
View Article and Find Full Text PDFA novel orf virus vector-based COVID-19 booster vaccine shows cross-neutralizing activity in the absence of anti-vector neutralizing immunity.
Hum Vaccin Immunother
December 2024
Speransa Therapeutics, TowerOne (Spaces), Frankfurt am Main, Germany.
Article Synopsis
- Next-generation COVID-19 vaccines aim to improve coverage against existing and future variants while extending protection duration; the Prime-2-CoV_Beta vaccine uses an ORF virus platform to present multiple antigens.
- A phase 1 trial (ORFEUS study) tested the safety and immune response of Prime-2-CoV_Beta in participants aged 18-55 and 65-85 who previously received mRNA vaccines, with doses administered on day 1 and day 29.
- Results showed that Prime-2-CoV_Beta is safe, well tolerated, and generates strong immune responses, especially in younger participants, suggesting the ORFV platform's potential for future vaccine development.
Multi-antigen intranasal vaccine protects against challenge with sarbecoviruses and prevents transmission in hamsters.
Nat Commun
July 2024
William A. Brookshire Department of Chemical and Biomolecular Engineering, University of Houston, Houston, TX, USA.
Immunization programs against SARS-CoV-2 with commercial intramuscular vaccines prevent disease but are less efficient in preventing infections. Mucosal vaccines can provide improved protection against transmission, ideally for different variants of concern (VOCs) and related sarbecoviruses. Here, we report a multi-antigen, intranasal vaccine, NanoSTING-SN (NanoSTING-Spike-Nucleocapsid), eliminates virus replication in both the lungs and the nostrils upon challenge with the pathogenic SARS-CoV-2 Delta VOC.
View Article and Find Full Text PDFNovel Multi-Antigen Orf-Virus-Derived Vaccine Elicits Protective Anti-SARS-CoV-2 Response in Monovalent and Bivalent Formats.
Vaccines (Basel)
May 2024
Speransa Therapeutics, Frankfurt am Main, 60327 Frankfurt, Germany.
Article Synopsis
- Prime-2-CoV_Beta is a new COVID-19 vaccine candidate that uses an Orf virus to express the nucleocapsid and spike proteins from SARS-CoV-2, specifically the Beta strain.
- In Phase I clinical trials, the vaccine was found to be safe and able to generate immune responses, but further studies were needed due to the evolving variants, particularly Omicron.
- Research in mice and hamsters showed that while Prime-2-CoV_Beta elicited strong immune responses in unvaccinated animals, it did not significantly boost immunity in already immunized subjects and demonstrated similar protection levels between different immunization strategies.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!